Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery
NCT ID: NCT03548597
Last Updated: 2018-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
132 participants
OBSERVATIONAL
2012-04-04
2016-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The XL probe of FibroScan was recently developed to realize liver stiffness measurements (LSM) in overweight patients.
Severe obese patients have a high prevalence of liver injuries and could benefit of liver evaluation prior to bariatric surgery.
Objectives:
Assess the FibroScan applicability, reliability and diagnostic performances in severe obese patients' candidates for bariatric surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
NCT03872024
EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
NCT02880189
Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients
NCT00926224
Fibrosis a New Pathological Actor in Adipose Tissue
NCT01655017
Fibrosis Reduction in Non Alcoholic Steatohepatitis
NCT05798702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Echosens
INDUSTRY
European Georges Pompidou Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Charles Barsamian
Doctor of Medicine
References
Explore related publications, articles, or registry entries linked to this study.
Barsamian C, Carette C, Sasso M, Poghosyan T, Bedossa P, Emile JF, Parlier D, Miette V, Bouillot JL, Czernichow S, Rives-Lange C. Diagnostic of hepatic fibrosis with the XL probe of the Fibroscan versus biopsies in patients candidates to bariatric surgery. Clin Nutr ESPEN. 2020 Jun;37:226-232. doi: 10.1016/j.clnesp.2020.02.010. Epub 2020 Mar 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B047
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.